Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins
US-2024131137-A1 · Apr 25, 2024 · US
Compositions comprising a chimeric bacterial surface layer protein and methods of use thereof
US11299520B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11299520-B2 |
| Application number | US-201816651160-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 25, 2018 |
| Priority date | Sep 26, 2017 |
| Publication date | Apr 12, 2022 |
| Grant date | Apr 12, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention features engineered probiotic lacto acid bacteria (LAB) expressing a chimeric Clostridium difficile/Lactobacillus acidophilus SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.
First claim
Opening claim text (preview).
What is claimed is: 1. A chimeric nucleic acid molecule comprising a nucleic acid sequence comprising a phosphoglycerate mutase (pgm) constitutive promoter (pgm promoter) operatively linked to a nucleic acid sequence encoding a chimeric bacterial surface layer protein A (SlpA) comprising a Clostridium difficile variable domain having at least 85% identity to a Clostridium difficile variable domain having the sequence corresponding to SEQ ID NO:15 and a lactic acid bacterium (LAB) peptidoglycan anchor having at least 85% identity to a LAB peptidoglycan anchor having the sequence corresponding to SEQ ID NO:14. 2. The chimeric nucleic acid molecule of claim 1 , wherein the pgm is from a Lactobacillus species selected from the group consisting of Lactobacillus acidophilus and Lactobacillus casei. 3. The chimeric nucleic acid molecule of claim 1 , wherein the LAB is Lactobacillus species selected from the group consisting of Lactobacillus acidophilus and Lactobacillus casei. 4. The chimeric nucleic acid molecule of claim 1 , wherein the nucleic acid sequence comprising the pgm promoter and the nucleic acid sequence encoding the chimeric bacterial SlpA has the nucleic acid sequence of SEQ ID NO: 18. 5. A method of treating or preventing Clostridium difficile infection in a mammal, the method comprising administering to the mammal an engineered cell comprising the chimeric nucleic acid molecule of claim 1 , thereby treating or preventing Clostridium difficile infection in the mammal. 6. The method of claim 5 , wherein the administered engineered cell is selected from the group consisting of Lactobacillus acidophilus , and Lactobacillus casei. 7. The method of claim 5 , wherein the engineered cell is administered orally. 8. The method of claim 5 , wherein the engineered cell is administered daily. 9. The method of claim 5 , wherein the mammal is a human.
Assignees
Inventors
Classifications
DNA sequences coding for fusion proteins · CPC title
Bacterial cells; Fungal cells; Protozoal cells · CPC title
from Lactobacillus (G) · CPC title
expressing foreign proteins · CPC title
- C07K14/33Primary
from Clostridium (G) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11299520B2 cover?
- The invention features engineered probiotic lacto acid bacteria (LAB) expressing a chimeric Clostridium difficile/Lactobacillus acidophilus SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.
- Who is the assignee on this patent?
- Univ Arizona
- What technology area does this patent fall under?
- Primary CPC classification C07K14/33. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).